

Addex Therapeutics Ltd (ADXN) - Financial and Strategic SWOT Analysis Review

URL:	https://marketpublishers.com/r/A0110ECFFC6EN.html
Date:	May 30, 2018
Pages:	42
Price:	US\$ 125.00
ID:	A0110ECFFC6EN

Addex Therapeutics Ltd (ADXN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company's operations and business divisions.
- Corporate strategy – Analyst's summarization of the company's business strategy.
- SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives' employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Addex Therapeutics Ltd (Addex) develops orally available, small molecule allosteric modulators for neurological disorders. The company's product pipeline consists of its lead products, dipraglurant (mGluR5 negative allosteric modulator or NAM) to treat Parkinson's disease levodopa-induced dyskinesia (PD-LID) and rare forms of dystonia; and ADX71149 (mGluR2 positive allosteric modulator or PAM) for the treatment of epilepsy. It also conducts clinical and preclinical development of drug candidates for indications such as addiction, Charcot-Marie-Tooth Type 1a (CMT1A) disease, spasticity in patients with multiple sclerosis (MS), pain, overactive bladder, autism and other disorders, Parkinson's disease, anxiety, resistant depression, cognitive deficits and psychosomatic disorders. Addex is headquartered in Plan-les-Ouates, Geneva, Switzerland.

Addex Therapeutics Ltd Key Recent Developments

Apr 30,2018: Addex Announces 2017 Full Year Results

Mar 20,2018: Swiss Takeover Board Validates New Article 39 (Opting-Out Provision) of Addex Articles of Association

Mar 19,2018: Addex Shareholders Approved all Board Proposals at Extraordinary General Meeting

Feb 07,2018: Addex Appoints Jean-Philippe Rocher as Co-Head of Discovery and Member of the Executive Management

Sep 26,2017: Addex Therapeutics Reports First Half 2017 Operating **Highlights** and Financial Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Content

SECTION 1 - ABOUT THE COMPANY

Addex Therapeutics Ltd - Key Facts

Addex Therapeutics Ltd - Key Employees

Addex Therapeutics Ltd - Key Employee Biographies

Addex Therapeutics Ltd - Major Products and Services

Addex Therapeutics Ltd - History

Addex Therapeutics Ltd - Company Statement

Addex Therapeutics Ltd - Locations And Subsidiaries

Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Addex Therapeutics Ltd - Business Description
Addex Therapeutics Ltd - Corporate Strategy
Addex Therapeutics Ltd - SWOT Analysis
SWOT Analysis - Overview
Addex Therapeutics Ltd - Strengths
Addex Therapeutics Ltd - Weaknesses
Addex Therapeutics Ltd - Opportunities
Addex Therapeutics Ltd - Threats
Addex Therapeutics Ltd - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY'S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Addex Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Addex Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Addex Therapeutics Ltd, Recent Deals Summary

SECTION 5 – COMPANY'S RECENT DEVELOPMENTS

Mar 20, 2018: Swiss Takeover Board Validates New Article 39 (Opting-Out Provision) of Addex Articles of Association
Mar 19, 2018: Addex Shareholders Approved all Board Proposals at Extraordinary General Meeting
Feb 07, 2018: Addex Appoints Jean-Philippe Rocher as Co-Head of Discovery and Member of the Executive Management
Sep 26, 2017: Addex Therapeutics Reports First Half 2017 Operating Highlights and Financial Results
Sep 18, 2017: Addex Makes Changes to Executive Management Team
Apr 05, 2017: Addex Therapeutics Provides Corporate Update and Reports 2016 Financial Results
Feb 06, 2017: Addex's Clinical Programs and Discovery Platform Highlighted in Review of Allosteric Modulators for the Treatment of Neurodegenerative Diseases
Jan 31, 2017: Addex Awarded \$835,000 Grant from Michael J. Fox Foundation to Advance TrkB PAMs for the Treatment of Parkinson's Disease

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Addex Therapeutics Ltd, Key Facts
Addex Therapeutics Ltd, Key Employees
Addex Therapeutics Ltd, Key Employee Biographies
Addex Therapeutics Ltd, Major Products and Services
Addex Therapeutics Ltd, History
Addex Therapeutics Ltd, Other Locations
Addex Therapeutics Ltd, Subsidiaries
Addex Therapeutics Ltd, Key Competitors
Addex Therapeutics Ltd, Ratios based on current share price
Addex Therapeutics Ltd, Annual Ratios
Addex Therapeutics Ltd, Annual Ratios (Cont.1)
Addex Therapeutics Ltd, Interim Ratios
Addex Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Addex Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Addex Therapeutics Ltd, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

LIST OF FIGURES

Addex Therapeutics Ltd, Performance Chart (2012 - 2016)
Addex Therapeutics Ltd, Ratio Charts
Addex Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Addex Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

COMPANIES MENTIONED

AstraZeneca Plc
F. Hoffmann-La Roche Ltd
MetrioPharm AG
Novartis AG
Siegfried Holding AG
Stragen Pharma SA

I would like to order:

Product name: Addex Therapeutics Ltd (ADXN) - Financial and Strategic SWOT Analysis Review
Product link: <https://marketpublishers.com/r/A0110ECFFC6EN.html>
Product ID: A0110ECFFC6EN
Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service: office@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click 'BUY NOW' button on product page <https://marketpublishers.com/r/A0110ECFFC6EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
E-mail:
Company:
Address:
City:
Zip/Post Code:
Country:
Tel:
Fax:
Your message:

* All fields are required

Customer Signature _____

Please, note that by ordering from MarketPublisher.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms_conditions.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to **+44 20 7900 3970**